PHARMACOKINETICS/PHARMACODYNAMICS OF A 8-LACTAM AND /8-LACTAMASE INHIBITOR COMBINATION: A NOVEL APPROACH FOR AZTREONAM/AVIBACTAM

PHARMACOKINETICS/PHARMACODYNAMICS OF A 8-LACTAM AND /8-LACTAMASE INHIBITOR COMBINATION: A NOVEL APPROACH FOR AZTREONAM/AVIBACTAM

Saved in:

Bibliographic Details
Main Authors:	R. .. Singh, A. .. Kim, M. A. Tanudra, J. J. Harris, R. E. Mclaughlin, S. .. Patey, J. P. O'donnell, P. A. Bradford, A. E. Eakin
Format:	Article
Language:	Russian
Published:	LLC "Publishing House OKI" 2020-05-01
Series:	Антибиотики и Химиотерапия
Online Access:	https://www.antibiotics-chemotherapy.ru/jour/article/view/638
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Contribution of efflux pump hyperactivity to the resistance to new β-lactam-β-lactamase inhibitor combinations including ceftazidime-avibactam, aztreonam-avibactam, and imipenem-relebactam
by: Sung Pin Tseng, et al.
Published: (2024-12-01)

Characterization of Metallo β-Lactamase Producing <i>Enterobacterales</i> Isolates with Susceptibility to the Aztreonam/Avibactam Combination
by: Brunella Posteraro, et al.
Published: (2024-12-01)

Antimicrobial susceptibility of enterobacterales causing bloodstream infection in United States medical centres: comparison of aztreonam-avibactam with beta-lactams active against carbapenem-resistant enterobacterales
by: Helio S. Sader, et al.
Published: (2024-11-01)

Synergistic combination of aztreonam and ceftazidime/avibactam against resistant Stenotrophomonas maltophilia on pancreatitis
by: Natália de Almeida Torres, et al.
Published: (2023-06-01)

Beta-lactam antibiotics use in intensive care units - the pathophysiological, pharmacokinetic, pharmacodynamic and pharmacoeconomic approach
by: Perić Aneta, et al.
Published: (2015-01-01)

In vitro activity of aztreonam–avibactam combination against blood culture isolates of Stenotrophomonas maltophilia in Japan before the launch of ceftazidime–avibactam
by: Wataru Aoki, et al.
Published: (2025-05-01)

CEFTOLOZANE/TAZOBACTAM AND CEFTAZIDIME/AVIBACTAM: TWO NOVEL в-LACTAM / β-LACTAMASE INHIBITOR COMBINATION AGENTS FOR THE TREATMENT OF RESISTANT GRAM-NEGATIVE BACTERIAL INFECTIONS
by: J. L. Liscio, et al.
Published: (2020-05-01)

In Vitro Activities of Aztreonam-avibactam and Comparator Agents against Metallo-β-lactamase-producing Enterobacterales Collected in the Middle East and Africa, ATLAS Global Surveillance Program, 2018-2022
by: Dr Mark Estabrook, et al.
Published: (2025-03-01)

Assessment of pharmacokinetics-pharmacodynamics relationship of tropoxine in rats
by: V. P. Zherdev, et al.
Published: (2016-09-01)

Mortality of metallo-β-lactamase-producing Enterobacterales bacteremias with combined ceftazidime–avibactam plus aztreonam vs. other active antibiotics: a multicenter target trial emulationResearch in context
by: Ivan Alfredo Huespe, et al.
Published: (2025-09-01)

Navigating pharmacokinetic and pharmacodynamics challenges of β-lactam antibiotics in patients with low body weight: efficacy, toxicity, and dosage optimization
by: Yu-Ju Tseng, et al.
Published: (2025-02-01)

Pharmacodynamic Evaluation of Adjuvant Targets: Low Molecular Weight PBP7/8 Effects on β-Lactam Activity Against Carbapenem-Resistant Acinetobacter Baumannii
by: Brian M. Ho, et al.
Published: (2025-06-01)

Carbapenem-resistant Klebsiella pneumoniae infections in Chinese children: in vitro activities of ceftazidime-avibactam and aztreonam-avibactam against carbapenemase-producing strains in a two-center study
by: Xia Ran, et al.
Published: (2025-03-01)

Whole-genome analysis of NDM-producing Providencia hangzhouensis associated with recurrent bacteraemia with rapid development of aztreonam-avibactam resistance
by: Ka Lip Chew, et al.
Published: (2025-12-01)

Tissue Distribution and Pharmacokinetic Characteristics of Aztreonam Based on Multi-Species PBPK Model
by: Xiao Ye, et al.
Published: (2025-06-01)

10th anniversary of the journal «Pharmacokinetics and pharmacodynamics»
by: V. P. Zherdev
Published: (2014-04-01)

On the 20th anniversary of the journal «Pharmacokinetics and Pharmacodynamics»
by: V. P. Zherdev
Published: (2024-06-01)

Suitability of Piperacillin–Tazobactam for Treating Dogs Infected with Extended-Spectrum β-Lactamase-Producing Enterobacterales: Pharmacokinetic and Pharmacodynamic Analysis
by: Kazuki Harada, et al.
Published: (2025-04-01)

Study on the invitro synergistic susceptibility and biofilm inhibition mechanism of ceftazidime-avibactam combined with aztreonam against carbapenem-resistant Klebsiella pneumoniae
by: Guangfen Wang, et al.
Published: (2025-03-01)

Aztreonam Acts as a Synergist for Ceftazidime/Avibactam Against Carbapenem-Resistant Enterobacteriaceae (CRE) of Various Carbapenemase Phenotypes in Southwestern China
by: Ruan X, et al.
Published: (2025-05-01)

Population pharmacokinetics and pharmacodynamics of edoxaban in pediatric patients
by: Peng Zou, et al.
Published: (2025-01-01)

Pharmacokinetic and pharmacodynamic data analysis : concepts and applications /
by: Gabrielsson, Johan
Published: (2016)

Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Milvexian in Healthy Chinese Adults
by: Luo Z, et al.
Published: (2025-03-01)

Oestrogene mimetic isoflavones’ pharmacokinetics and pharmacodynamics
by: Anca Dragomirescu,, et al.
Published: (2008-12-01)

Pharmacodynamics of meropenem and meropenem combined with avibactam against Klebsiella pneumoniae in an in vitro dynamic model
by: Strukova E.N., et al.
Published: (2025-03-01)

In vitro Evaluation of the Antibacterial Activity of the Combination of Avibactam and β-Lactams Against Highly Virulent Carbapenem-Resistant Klebsiella pneumoniae
by: Chang J, et al.
Published: (2025-04-01)

Antimicrobial Susceptibility Testing of the Combination of Aztreonam and Avibactam in NDM-Producing <i>Enterobacterales</i>: A Comparative Evaluation Using the CLSI and EUCAST Methods
by: Linda Mei-Wah Chan, et al.
Published: (2025-07-01)

Susceptibility of Enterobacterales Collected in the Middle East and Turkey to Aztreonam/Avibactam and Comparator Agents Stratified by Infection Source: ATLAS Surveillance Program 2018-2022
by: Mark Wise, et al.
Published: (2024-12-01)

β-Lactam/β-Lactamase Inhibitor Combination Antibiotics Under Development
by: Angeliki Katsarou, et al.
Published: (2025-02-01)

In vitro activity of aztreonam in combination with relebactam against gram-negative pathogens producing various serine and metallo-β-lactamases
by: Kengo Hayashi, et al.
Published: (2025-05-01)

General Anesthetics: Aspects of Chirality, Pharmacodynamics, and Pharmacokinetics
by: Ružena Čižmáriková, et al.
Published: (2025-02-01)

Eradication of Burkholderia cepacia Using Inhaled Aztreonam Lysine in Two Patients with Bronchiectasis
by: A. Iglesias, et al.
Published: (2014-01-01)

Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Analyses of Pegcetacoplan in Patients with Paroxysmal Nocturnal Hemoglobinuria
by: Ryan L. Crass, et al.
Published: (2024-11-01)

Evaluation of pharmacokinetic pharmacodynamic target attainment of meropenem in pediatric patients
by: Abdullah Alsultan, et al.
Published: (2024-07-01)

In Vitro Activity of Aztreonam-avibactam and Comparator Agents Against Carbapenemase-producing Enterobacterales Collected in Turkey and the Middle East as Part of the ATLAS Surveillance Program: 2018-2022
by: Mark Estabrook, et al.
Published: (2024-12-01)

Longitudinal Analysis of the In Vitro Activity of Aztreonam-Avibactam and Comparator Agents Against Enterobacterales Collected in the Middle East/Africa Region for the ATLAS Surveillance Program, 2018-2022
by: Dr Mark Wise, et al.
Published: (2025-03-01)

Exploring Apixaban Pharmacokinetics, Pharmacodynamics, and Safety in Hemodiafiltration Patients
by: Aurema Otero, et al.
Published: (2024-09-01)

Editorial on Special Issue “Pharmacokinetics, Pharmacodynamics, and Drug Interactions”
by: Zhu Zhou
Published: (2025-02-01)

Insulin glargine: pharmacokinetic and pharmacodynamic basis of clinical effect
by: Vadim Valer'evich Klimontov, et al.
Published: (2014-12-01)

Pharmacokinetic and pharmacodynamic assessment of oral nicotinamide in the NEAT clinical trial for early Alzheimer’s disease
by: Gabriel L Ketron, et al.
Published: (2025-03-01)